{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T13:09:53Z","timestamp":1686402593381},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,7,9]],"date-time":"2011-07-09T00:00:00Z","timestamp":1310169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s11912-011-0185-9","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T15:18:28Z","timestamp":1310138308000},"page":"371-378","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults"],"prefix":"10.1007","volume":"13","author":[{"given":"Joseph M.","family":"Brandwein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,9]]},"reference":[{"key":"185_CR1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95\u201301 for children with acute lymphoblastic leukemia. Blood. 2007;109:896\u2013904.","journal-title":"Blood"},{"key":"185_CR2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/leu.2009.256","volume":"24","author":"C Mitchell","year":"2010","unstructured":"Mitchell C, Richards S, Harrison CJ, et al. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukemia, 1980\u20132001. Leukemia. 2010;24:406\u201318.","journal-title":"Leukemia"},{"key":"185_CR3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/leu.2009.262","volume":"24","author":"PS Gaynon","year":"2010","unstructured":"Gaynon PS, Angiolilo AL, Carroll WL, et al. Long-term results of the children\u2019s cancer group studies for childhood acute lymphoblastic leukemia 1983\u20132202: A Children\u2019s Oncology Group Report. Leukemia. 2010;24:284\u201397.","journal-title":"Leukemia"},{"key":"185_CR4","first-page":"3310","volume":"95","author":"M Schrappe","year":"2000","unstructured":"Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310\u201322.","journal-title":"Blood"},{"key":"185_CR5","first-page":"87","volume":"4","author":"VM Santana","year":"1990","unstructured":"Santana VM, Dodge RK, Crist WM, et al. Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia. Leukemia. 1990;4:87\u201390.","journal-title":"Leukemia"},{"key":"185_CR6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00277-002-0551-7","volume":"81","author":"G Irken","year":"2002","unstructured":"Irken G, Oren H, G\u00fclen H, et al. Treatment outcome of adolescents with acute lymphoblastic leukemia. Ann Hematol. 2002;81:641\u20135.","journal-title":"Ann Hematol"},{"key":"185_CR7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","volume":"21","author":"N Boissel","year":"2003","unstructured":"Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 Trials. J Clin Oncol. 2003;21:774\u201380.","journal-title":"J Clin Oncol"},{"key":"185_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","volume":"48","author":"R Ramanujachar","year":"2007","unstructured":"Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials. Pediatr Blood Cancer. 2007;48:254\u201361.","journal-title":"Pediatr Blood Cancer"},{"key":"185_CR9","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","volume":"18","author":"TM Bont de","year":"2004","unstructured":"de Bont TM, van der Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18:2032\u20135.","journal-title":"Leukemia"},{"key":"185_CR10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","volume":"25","author":"E Barry","year":"2007","unstructured":"Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols. J Clin Oncol. 2007;25:813\u20139.","journal-title":"J Clin Oncol"},{"key":"185_CR11","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","volume":"112","author":"W Stock","year":"2008","unstructured":"Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646\u201354.","journal-title":"Blood"},{"key":"185_CR12","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1200\/JCO.2008.20.8959","volume":"27","author":"JB Nachman","year":"2009","unstructured":"\u2022 Nachman JB, La, MK, Hunger SP, et al: Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: A report from the Children's Oncology Group. J Clin Oncol 2009; 27:5189\u20135194. Shows improved results with early intensification.","journal-title":"J Clin Oncol"},{"key":"185_CR13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","volume":"29","author":"C-H Pui","year":"2011","unstructured":"\u2022 Pui C-H, Pei D, Campana D, et al: Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2011; 29:386\u2013391. St. Jude\u2019s study demonstrating that, with most current regimen, differences in outcome between adolescents and younger children have been abolished.","journal-title":"J Clin Oncol"},{"key":"185_CR14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","volume":"16","author":"J Takeuchi","year":"2002","unstructured":"Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93. Leukemia. 2002;16:1259\u201366.","journal-title":"Leukemia"},{"key":"185_CR15","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood. 2008;111:1827\u201333.","journal-title":"Blood"},{"key":"185_CR16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","volume":"26","author":"J-M Ribera","year":"2008","unstructured":"Ribera J-M, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young dults with standard-risk acute lymphoblastic leukemia with the Programa Espa\u00f1ol de Tratamiento en Hematolog\u00eda Pediatric-Based Protocol ALL-96. J Clin Oncol. 2008;26:1843\u20139.","journal-title":"J Clin Oncol"},{"key":"185_CR17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","volume":"27","author":"F Huguet","year":"2009","unstructured":"Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia Chromosome\u2013negative acute lymphoblastic leukemia: The GRAALL-2003 Study. J Clin Oncol. 2009;27:911\u20138.","journal-title":"J Clin Oncol"},{"key":"185_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","volume":"146","author":"JM Storring","year":"2009","unstructured":"\u2022 Storring JM, Minden MD, Kao S, et al: Treatment of Adults with BCR-ABL Negative Acute Lymphoblastic Leukemia (ALL) with a Modified Pediatric Regimen. Br J Haematol 2009; 146:76\u201385. Best results to date with pediatric-based regimen in adults age 18\u201335; also emphasizes toxicity issues.","journal-title":"Br J Haematol"},{"key":"185_CR19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/10428190903388376","volume":"51","author":"M Al-Khabori","year":"2010","unstructured":"Al-Khabori M, Minden MD, Yee KWY, et al. Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell Acute Lymphoblastic Leukemia. Leukemia and Lymphoma. 2010;51:61\u20135.","journal-title":"Leukemia and Lymphoma"},{"key":"185_CR20","doi-asserted-by":"crossref","first-page":"526a","DOI":"10.1182\/blood-2006-02-005702","volume":"108","author":"DJ DeAngelo","year":"2006","unstructured":"DeAngelo DJ, Silverman LB, Couban S, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood. 2006;108:526a.","journal-title":"Blood"},{"key":"185_CR21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91\u201301. Blood. 2001;97:1211\u20138.","journal-title":"Blood"},{"key":"185_CR22","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","volume":"113","author":"DA Thomas","year":"2009","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113:6330\u20137.","journal-title":"Blood"},{"key":"185_CR23","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3324\/haematol.2009.021089","volume":"95","author":"H Chang","year":"2010","unstructured":"Chang H, Jiang A, Xu W, Brandwein J. Therapy may influence the prognostic significance of CD20 expression in precursor-B acute lymphoblastic leukemia. Haematologica. 2010;95:1040\u20132.","journal-title":"Haematologica"},{"key":"185_CR24","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2004-07-2922","volume":"105","author":"M Mancini","year":"2005","unstructured":"Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105:3434\u201341.","journal-title":"Blood"},{"key":"185_CR25","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","volume":"111","author":"V Pullarkat","year":"2008","unstructured":"Pullarkat V, Slovak ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111:2563\u201372.","journal-title":"Blood"},{"key":"185_CR26","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GAN, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189\u201397.","journal-title":"Blood"},{"key":"185_CR27","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome frm the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114:5136\u201345.","journal-title":"Blood"},{"key":"185_CR28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7326\/0003-4819-123-6-199509150-00006","volume":"123","author":"MJ Zhang","year":"1995","unstructured":"Zhang MJ, Hoelzer D, Horowitz MM, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med. 1995;123:428\u201331.","journal-title":"Ann Intern Med"},{"key":"185_CR29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0889-8588(05)70190-8","volume":"14","author":"A Thiebaut","year":"2000","unstructured":"Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia sudy testng chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin N Amer. 2000;14:1353\u201366.","journal-title":"Hematol Oncol Clin N Amer"},{"key":"185_CR30","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/sj.leu.2404420","volume":"20","author":"N Vey","year":"2006","unstructured":"Vey N, Thomas X, Picard C, et al. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)\/E2A-PBX1 and t(4;11)\/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006;20:2155\u201361.","journal-title":"Leukemia"},{"key":"185_CR31","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood-2010-02-269571","volume":"116","author":"S Nishiwaki","year":"2010","unstructured":"Nishiwaki S, Inamoto Y, Sakamaki, et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome\u2013negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood. 2010;116:4368\u201375.","journal-title":"Blood"},{"key":"185_CR32","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Copra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109:944\u201350.","journal-title":"Blood"},{"key":"185_CR33","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome \u2013positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over the chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood. 2009;113:4489\u201396.","journal-title":"Blood"},{"key":"185_CR34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.bmt.1704368","volume":"33","author":"V Gupta","year":"2004","unstructured":"Gupta V, Yi Q, Brandwein J, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55\u00a0years with acute lymphoblastic leukemia (ALL) in first complete remission: A donor vs no donor comparison. Bone Marrow Transplantation. 2004;33:397\u2013404.","journal-title":"Bone Marrow Transplantation"},{"key":"185_CR35","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron J-M, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lympholastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357\u201366.","journal-title":"Blood"},{"key":"185_CR36","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.V112.11.2931.2931","volume":"112","author":"DA Thomas","year":"2008","unstructured":"Thomas DA, Kantarjian HM, Cortes J, et al. Outcome after frontline therapy with the Hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood. 2008;112:2931.","journal-title":"Blood"},{"key":"185_CR37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A Labarthe de","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109:1408\u201313.","journal-title":"Blood"},{"key":"185_CR38","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","volume":"28","author":"R Bassan","year":"2010","unstructured":"Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased Imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group Protocol 09\/00. J Clin Oncol. 2010;28:3644\u201352.","journal-title":"J Clin Oncol"},{"key":"185_CR39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2010-01-242750","volume":"116","author":"AK Fielding","year":"2010","unstructured":"Fielding AK, Buck G, Lazarus HM, et al. Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia; Final Results of the UKALLXII\/ECOG2993 Trial. Blood. 2010;116:169.","journal-title":"Blood"},{"key":"185_CR40","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O\u2019Brien S, Thomas D, et al. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome\u2013positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070\u20137.","journal-title":"Blood"},{"key":"185_CR41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","volume":"152","author":"RF Grace","year":"2011","unstructured":"Grace RF, Dahlberg SE, Neuber D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukemia treated on Dana Farber Institute Consortium protocols. Br J Haematol. 2011;152:452\u20139.","journal-title":"Br J Haematol"},{"key":"185_CR42","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","volume":"115","author":"L Mitchell","year":"2010","unstructured":"Mitchell L, Lambers M, Flege S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood. 2010;115:4999\u20135004.","journal-title":"Blood"},{"key":"185_CR43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2405032","volume":"22","author":"B Patel","year":"2008","unstructured":"Patel B, Richards SM, Rowe JM, et al. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukemia: a UKALL XII analysis. Leukemia. 2008;22:308\u201312.","journal-title":"Leukemia"},{"key":"185_CR44","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2006.07.9947","volume":"25","author":"EJ Karimona","year":"2007","unstructured":"Karimona EJ, Rai SN, Howard SC, et al. femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol. 2007;25:1525\u201331.","journal-title":"J Clin Oncol"},{"key":"185_CR45","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood-2007-11-123885","volume":"111","author":"D French","year":"2008","unstructured":"French D, Hamilton LH, Mattano LA, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood. 2008;111:4496\u20139.","journal-title":"Blood"},{"key":"185_CR46","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1084\/jem.188.9.1563","volume":"188","author":"I Borcsok","year":"1998","unstructured":"Borcsok I, Schairer HU, Sommer U, et al. Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene. J Exp med. 1998;188:1563\u201373.","journal-title":"J Exp med"},{"key":"185_CR47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jsbmb.2009.05.001","volume":"116","author":"MA Kerachian","year":"2009","unstructured":"Kerachian MA, Cournoyer D, Harvey EJ, et al. Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion. J Steroid Biochem Mol Biol. 2009;116:127\u201333.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"185_CR48","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/pbc.22428","volume":"54","author":"RS Kotecha","year":"2010","unstructured":"Kotecha RS, Powere N, Lee SJ, et al. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). Pediatric Blood Cancer. 2010;54:934\u201340.","journal-title":"Pediatric Blood Cancer"},{"issue":"2","key":"185_CR49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","volume":"54","author":"LM Vrooman","year":"2010","unstructured":"Vrooman LM, Supko JG Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatric Blood Cancer. 2010;54(2):199\u2013205.","journal-title":"Pediatric Blood Cancer"},{"key":"185_CR50","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/14712591003769808","volume":"10","author":"M Rytting","year":"2010","unstructured":"Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther. 2010;10:833\u20139.","journal-title":"Expert Opin Biol Ther."},{"key":"185_CR51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"V Velden van der","year":"2007","unstructured":"van der Velden V, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines of interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia"},{"key":"185_CR52","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","volume":"115","author":"V Conter","year":"2010","unstructured":"\u2022 Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with -cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206\u20133214. Demonstrates importance of MRD detection in young patients with ALL.","journal-title":"Blood"},{"key":"185_CR53","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","volume":"115","author":"P Stow","year":"2010","unstructured":"Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010;115:4657\u201363.","journal-title":"Blood"},{"key":"185_CR54","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","volume":"113","author":"R Bassan","year":"2009","unstructured":"Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153\u201362.","journal-title":"Blood"},{"key":"185_CR55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2008.07185.x","volume":"142","author":"J Holowiecki","year":"2008","unstructured":"Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4\u20132002 MRD Study. Br J Haematol. 2008;142:227\u201337.","journal-title":"Br J Haematol"},{"key":"185_CR56","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3324\/haematol.10965","volume":"92","author":"O Spinelli","year":"2007","unstructured":"Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612\u20138.","journal-title":"Haematologica"},{"key":"185_CR57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V116.21.170.170","volume":"116","author":"D Hoelzer","year":"2010","unstructured":"Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high-risk patients: Results of 263 CD20+ patients studied prospectively in GMALL study 08\/2003. Blood. 2010;116:170.","journal-title":"Blood"},{"key":"185_CR58","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880\u20139.","journal-title":"J Clin Oncol"},{"key":"185_CR59","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood.V116.21.174.174","volume":"116","author":"MS Topp","year":"2010","unstructured":"Topp MS, Zugmaier G, Goekbuget N, et al. CD19\/CD3 bispecific antibody blinatumomab (MT-103) is highly effective in treatment of patients with minimal residual disease from chemotherapy-resistant B-precursor acute lymphoblastic leukemia. Blood. 2010;116:174.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-011-0185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-011-0185-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-011-0185-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T19:44:37Z","timestamp":1638042277000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-011-0185-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,9]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1007\/s11912-011-0185-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,9]]}}}